Tyra Biosciences to Present at Upcoming Investor Conferences

Rhea-AI Summary

Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotechnology firm specializing in precision medicines for FGFR biology, will participate in several investor conferences. On May 28-29, 2024, CEO Todd Harris will join a fireside chat at TD Cowen's Oncology Innovation Summit. The company will engage in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 5-6, 2024. Additionally, Harris will present on June 12, 2024, at the Goldman Sachs Global Healthcare Conference, with further investor meetings scheduled. Webcasts of these presentations will be available on Tyra's Investor page.

Positive

• Tyra Biosciences will gain exposure by participating in prestigious investor conferences.
• CEO Todd Harris will engage directly with investors, potentially boosting investor confidence.
• Webcasts will provide transparency and broader access to company presentations.

Negative

• The press release lacks specific financial updates or clinical trial results, providing new information for investors.
• Participation in conferences does not directly correlate with immediate financial or clinical advancements.

CARLSBAD, Calif., May 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences:

• TD Cowen's 5^th Annual Oncology Innovation Summit: Insights for ASCO & EHA, May 28-29, 2024: Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, May 28, 2024, at 1:00 pm ET. 
• Jefferies Global Healthcare Conference, June 5-6, 2024: TYRA management will participate in one-on-one meetings with investors during the conference. 
• 45^th Annual Goldman Sachs Global Healthcare Conference, June 10-13, 2024: Todd Harris, CEO of TYRA, will present on Wednesday, June 12, 2024, at 8:40 am ET.  TYRA management will also participate in one-on-one meetings with investors during the conference.

A live and archived webcast of the presentations will be available via the For Investors page on the Investor section of the TYRA website. 

About Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA. 

For more information about our science, pipeline and people, please visit  www.tyra.bio and engage with us on LinkedIn.

Contact:

Amy Conrad
aconrad@tyra.bio

View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-upcoming-investor-conferences-302154687.html

SOURCE Tyra Biosciences

FAQ

When will Tyra Biosciences present at the TD Cowen's Oncology Innovation Summit?

CEO Todd Harris will participate in a fireside chat on May 28, 2024, at 1:00 pm ET.

What are the dates for Tyra Biosciences' participation in the Jefferies Global Healthcare Conference?

Tyra Biosciences will participate on June 5-6, 2024, with one-on-one investor meetings.

When is Tyra Biosciences presenting at the Goldman Sachs Global Healthcare Conference?

CEO Todd Harris will present on June 12, 2024, at 8:40 am ET.

How can investors view the presentations from these conferences?

Live and archived webcasts of the presentations will be available via the For Investors page on Tyra's Investor section of their website.